Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / Sensorion

Clinicaltrial registered17 Nov 2026

Sensorion

17 Nov 2026: Trial registered · A Clinical Trial With SENS-601, Injected With SPHYNX Administration System, in the Pediatric Population Presenting With Hearing Loss Related to Pathogenic Variation(s) of GJB2 Gene. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
17 Nov 2026
Title
A Clinical Trial With SENS-601, Injected With SPHYNX Administration System, in the Pediatric Population Presenting With Hearing Loss Related to Pathogenic Variation(s) of GJB2 Gene
Conditions
GJB2 Gene Mutation, DFNB1A, Congenital Deafness, Hearing Disorders
Phase
Phase 1, Phase 2
Study Type
Interventional
Status
Recruiting
Countries
France
Country
France
Reference
NCT07941115
Location
France
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Sensorion

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

More from France

New Clinical Trials

See all

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.